This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
American Well Corporation (AMWL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
American Well Corporation (AMWL) delivered earnings and revenue surprises of 0% and 3.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
American Well Corporation (AMWL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
American Well Corporation (AMWL) delivered earnings and revenue surprises of -18.18% and 0.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for American Well (AMWL)
by Zacks Equity Research
American Well (AMWL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
American Well Corporation (AMWL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
American Well Corporation (AMWL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Should You Stay Away From Teladoc Health (TDOC) Now?
by Zacks Equity Research
Rising competition and decreasing business volumes place Teladoc Health (TDOC) in a precarious position.
American Well (AMWL) Down 59% YTD: Should You Still Hold?
by Zacks Equity Research
American Well (AMWL) is well placed in the booming telehealth industry on the back of its organic and inorganic growth profiles.
Amwell (AMWL) Buys Digital Care Startups to Enhance Market Share
by Zacks Equity Research
Amwell (AMWL) acquires digital health startups for fast expansion in the telehealth market.
American Well (AMWL) Q2 Earnings Beat, 2H21 Visit View Cut
by Zacks Equity Research
American Well (AMWL) posts lower-than-expected loss for Q2. The spread of Delta variant compels the company to slash 2021 guidance.
Teladoc Health (TDOC) Q2 Loss Wider Than Expected, Worsen Y/Y
by Zacks Equity Research
Teladoc Health's (TDOC) Q2 earnings endure high expenses. Guidance shows tapering of growth.
Here's Why You Should Hold Teladoc Health (TDOC) in Your Portfolio
by Zacks Equity Research
Despite a great run on the bourses last year, Teladoc Health (TDOC) suffers tepid demand while stiff competition calls for keeping a close watch on the stock.
The Zacks Analyst Blog Highlights: GoodRx Holdings, American Well Corp, Accolade, SOC Telemed and Teladoc
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GoodRx Holdings, American Well Corp, Accolade, SOC Telemed and Teladoc
Booming Telehealth Market Lures More IPOs and M&A Deals
by Sapna Bagaria
To make the most of the booming telehealth industry, players are coming up with IPOs and resorting to mergers and acquisitions.
SOC Telemed (TLMD) Aids Virtual Service Expansion of SCP Health
by Sapna Bagaria
SOC Telemed (TLMD) offers its cloud-based Telemed IQ platform to expedite SCP Health's virtual care expansion.
Will Teladoc (TDOC) Feel the Heat From SOC Telemed's Expansion?
by Zacks Equity Research
SOC Telemed's fund-raising program through investors for the second consecutive year to expand its operations might intensify competition for Teladoc Health (TDOC).
Will Teladoc's (TDOC) New Service Seize the Mental Health Space?
by Zacks Equity Research
Teladoc Health (TDOC) rolls out a complete mental care offering to tap the growing market for behavioral health care.
Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) sturdy consumer cannabis sales are likely to have benefited its performance in the fiscal third quarter.
Why American Well (AMWL) Might Surprise This Earnings Season
by Zacks Equity Research
American Well (AMWL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Schrodinger (SDGR) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Schrodinger's (SDGR) first-quarter results are likely to reflect benefits from collaborations.
What's in Store for Asensus Surgical's (ASXC) Q1 Earnings?
by Zacks Equity Research
Asensus Surgical's (ASXC) first-quarter results are likely to reflect benefits from regulatory approvals and collaboration.
American Axle (AXL) to Report Q1 Earnings: What Lies Ahead?
by Zacks Equity Research
American Axle's (AXL) Q1 results likely to reflect benefits of solid top-line growth across both of the company's segments during the January-March period.
Will Surging Sales in China Drive General Motors' (GM) Q1 Earnings?
by Zacks Equity Research
General Motors' (GM) enhanced product line-up and customer-centric offerings in China are likely to have boosted the auto giant's Q1 earnings.
Teladoc (TDOC) Q1 Earnings Beat, 2021 Revenue Guidance Up
by Zacks Equity Research
Teladoc's (TDOC) Q1 results reflect revenue increase, led by higher membership and visits, partly offset by flared-up expenses.
Here's Why Cummins (CMI) is Poised for Q1 Earnings Beat
by Zacks Equity Research
Cummins' (CMI) Q1 results likely to reflect gains from rising sales across all major segments during the March-end quarter.
Factors Shaping the Fate of General Motors' (GM) Q1 Earnings
by Zacks Equity Research
Rising vehicle deliveries in the United States and China likely to have boosted General Motors' (GM) margins during the January-March period.
Will Vaccine Under the Lens Aid Teladoc's (TDOC) Prospects?
by Zacks Equity Research
Teladoc Health (TDOC) is likely to gain as the J&J-AstraZeneca vaccine comes under the microscope. This will likely slacken the vaccination drive, causing investors to shift to at-home stocks.